Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).
- Exchange
- nasdaq
- Notice
- delisting notice
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2), 5810(c)(3)(A)(iii)
Exact text from the filing
January 3, 2023, the Company received a letter from the Staff notifying it that, as of December 30, 2022, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days during the Minimum Bid Price Rule Compliance Period and, therefore, as contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii), the Company’s common stock will be delisted from The Nasdaq Capital Market. Nasdaq indicated that it would suspend trading in the Company’s common stock at the opening of business on January 12, 2023 and file a Form 25-NSE with the Securities and Exchange Commiss
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.95
Panbela Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
August 19, 2022, Panbela Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) (the “Minimum Equity Rule”) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000. The Company submitted to Nasdaq a plan to regain compliance with the Minimum Equity Rule and was grant
View on SEC.gov